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Abstract
Genome-wide association studies have been successful at identifying common disease variants associated with
complex diseases, but the common variants identified have small effect sizes and account for only a small fraction
of the estimated heritability for common diseases. Theoretical and empirical studies suggest that rare variants,
which are much less frequent in populations and are poorly captured by single-nucleotide polymorphism chips,
could play a significant role in complex diseases. Several new statistical methods have been developed for the
analysis of rare variants, for example, the combined multivariate and collapsing method, the weighted-sum method
and a replication-based method. Here, we apply and compare these methods to the simulated data sets of
Genetic Analysis Workshop 17 and thereby explore the contribution of rare variants to disease risk. In addition, we
investigate the usefulness of extreme phenotypes in identifying rare risk variants when dealing with quantitative
traits. Finally, we perform a pathway analysis and show the importance of the vascular endothelial growth factor
pathway in explaining different phenotypes.
Background
In disease association studies, the common disease/com-
mon variants (CDCV) model states that common dis-
eases are caused by common variants with minor allele
frequencies (MAFs) in the range of 1–5%. Recent stu-
dies suggest that although many more common disease
susceptibility variants may still exist, they will likely
have even smaller effect sizes and thus will be unlikely
to explain most of the missing heritability for many of
the traits [1]. On the other hand, the common disease/
rare variants (CDRV) hypothesis assumes that complex
disorders are caused by multiple rare variants (with
MAF < 1% or 5%), most of which are missense muta-
tions that can alter gene expression level or change
amino acid sequences directly [2,3]. Therefore the detec-
tion and investigation of rare variants will help research-
ers further understand the disease etiology and may
provide new insights into medical treatments. With the
development of next-generation sequencing technolo-
gies, large numbers of single-nucleotide polymorphisms
(SNPs) with low frequencies can be detected in a rela-
tively short time and at relatively low cost [4], making
the association study with rare variants increasingly
feasible.
Many statistical methods have been developed to test
association between common SNPs and disease traits,
but these methods have low power for identifying rare
variants in complex diseases because of the low frequen-
cies and large number of such variants [5,6]. Several
new methods have been developed that analyze all rare
variants in a gene or a candidate region. Li and Leal [7]
proposed one of the first statistical methods for the ana-
lysis of rare variants; their method is based on testing
whether the proportion of carriers of rare variants is sig-
nificantly different between case and control groups. A
subsequent paper by Madsen and Browning [8] intro-
duced the concept of weighting variants according to
their estimated frequencies in control subjects so that
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with more common variants. Price et al. [9] extended
the weighted-sum approach of Madsen and Browning to
weight variants according to externally defined weights,
such as predictions about the probability of a variant to
be functional. Ionita-Laza et al. [10] developed a new
approach, also based on a weighted-sum statistic, that
can be more powerful than the other methods men-
tioned, especially in larger genetic regions and in cases
where a mixture of risk and protective variants is pre-
sent in the region of interest.
In this paper, we apply these methods to the simulated
data sets provided by Genetic Analysis Workshop 17
(GAW17) to analyze the effect of rare variants on var-
ious phenotypes and evaluate the performance of each
method by comparing the results with the true disease
model. We also study the effect of trait dichotomization
when dealing with quantitative traits. In addition, we
investigate the importance of the vascular endothelial
growth factor (VEGF) pathway to different phenotypes
in the GAW17 data set.
Methods
Data set
The simulated data set from GAW17 consists of 3,205
autosomal genes with 24,487 SNPs genotyped on 697
subjects. Three quantitative phenotypes (Q1, Q2, Q4)
and the Affected Status phenotype are generated for
each of the unrelated individuals, and 200 simulated
replicates are available to us. In particular, each simula-
tion contains 209 case subjects and 488 control subjects
for the Affected Status phenotype and three normally
distributed quantitative traits (Q1, Q2, Q4). In the dis-
ease model, Q1 is caused by SNPs in the VEGF pathway
and Q2 is caused by SNPs related to cardiovascular risk
and inflammation; the trait Affected Status is affected by
SNPs from both biological processes. See Blangero et al.
[11] for more details on the simulation model.
Statistical testing strategies
We implemented three recently developed strategies for
association testing with rare variants: the gene-based
combined multivariate and collapsing (CMC) method of
Li and Leal [7], the weighted-sum (WS) method of
Madsen and Browning [8], and the replication-based
(RB) approach of Ionita-Laza [10] in our own R software
package. Briefly, the CMC method is used to test the
difference in the proportion of rare variant carriers
between case and control subjects. The WS method
assigns higher weight to variants less frequent in control
subjects and obtains a weighted-sum score from case
subjects. The RB approach is based on partitioning
observed variants into two disjoint classes (likely to be
risk or protective) and uses a weighting scheme that
reflects the difference in observed frequencies between
case and control subjects. See Dering et al. [12] for
more descriptions of the CMC and WS methods; the
RB approach is described in full detail by Ionita-Laza
et al. [10].
Strategies for quantitative traits
Because the methods mentioned are designed for case-
control studies, we make some adjustments in order to
apply them to quantitative traits. First, we dichotomize
the quantitative traits by treating the individuals in the
upper quartile as case subjects and those in the lower
quartile as control subjects and then apply the CMC,
WS, and RB methods to these pseudo-case-control data.
Another strategy that uses all the available data is to use
the modified weighted-sum test suggested by Price et al.
[9] in which each SNP’s weight is calculated on the
basis of its frequency in all subjects.
Pathway analysis
T h et r u ed i s e a s em o d e ls u g g e s t st h a tQ 1a n dA f f e c t e d
Status are affected by genes from the VEGF pathway
[11]; therefore we collapsed all the rare variants in the
VEGF pathway and performed a pathway-based analysis.
We searched the VEGF signaling pathway in the KEGG
database (http://www.genome.jp/kegg/pathway.html) and
in the NCI-pathway interaction database (http://pid.nci.
nih.gov/) and found that 53 genes in GAW17 data sets
participate in the VEGF pathway. We grouped the 344
rare SNPs (MAF < 0.05, with 173 nonsynonymous
SNPs) from these 53 genes and evaluated their effects
on Affected Status and Q1.
Results and discussion
Prominence of rare variants
A preliminary analysis indicates that the distribution of
SNP frequencies is heavily skewed toward low frequen-
cies. In particular, about 87% of SNPs have a MAF less
than 0.05, and about 74% have a MAF less than 0.01.
Motivated by the large proportion of rare variants, we
decided to investigate their effects on different pheno-
types even without prior knowledge of the true disease
model.
We applied the gene-based CMC, WS, and RB meth-
ods for the case-control design and dichotomized quan-
titative traits; we used Price’s method for quantitative
traits only. For each gene we computed the p-value and
the relative rank of the gene among all genes in each
method, using only the first simulated data set. We also
obtained the power (or replicability) for each gene, cal-
culated as the percentage of times the resulting gene-
based p- v a l u ew a sl e s st h a n0 . 0 5a c r o s st h e2 0 0r e p l i -
cates. After the true disease model was reviewed in
GAW17, our results were compared with the true
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sal genes that rank in the top 50 with any of the
methods.
Effect of minor allele frequency on power
In our analyses, we set two different thresholds to define
rare variants: MAF < 0.01 (T1) or MAF < 0.05 (T5). We
note here that the results from T1 and T5 are consistent
but using T5 tends to give higher power compared to
T1 because the sample size (697) is relatively small and
the disease model involves variants with MAF greater
than 0.01. Therefore, for the sake of clarity, we report
here and in Table 1 only the results from using cutoff
T5. In this data set, there are 21,355 rare SNPs with
MAF < 0.05, and 12,193 of them are nonsynonymous
SNPs, which we analyzed using various approaches.
Disease genes identified in the first simulation
We observe that for case-control or dichotomized quan-
titative trait designs, p-values and their ranks from the
W S ,C M C ,a n dR Bm e t h o d sh ighly agree with each
other; this makes us confident about the true effect if
we observe strong signals across different methods. Our
analyses included either all the genes (2,874 in total)
harboring rare variants or only those genes (1,999 in
total) containing nonsynonymous rare variants. Among
these genes, FLT1 is the easiest to identify. For Q1,
FLT1 is statistically significant with p-values less than
the Bonferroni-corrected significance level (~1.67 × 10
−5) and ranks first among all genes in the first simula-
tion. For Affected Status, FLT1 has a very low p-value,
close to the Bonferroni-corrected threshold, especially
when only nonsynonymous rare mutations are used. For
Q2, disease gene VNN3 is top-ranked with all three
methods.
For quantitative traits, the two strategies (dichotomi-
zation or not) result in different risk genes being
detected; in particular, dichotomization identifies more
genes with higher power compared with Price’s method.
This is partly because dichotomization likely eliminates
rare disease variants contained only in individuals with
modest phenotype values but it amplifies the signal for
Table 1 p-values and ranks of disease genes among all genes using the first simulated data set and their power
estimates across 200 simulations
Phenotype Gene p-values and ranks Power
WS CMC RB Price et al. [9] (Q-traits only)
Affected
status
FLT1 9.0 × 10
−4/1.9 × 10
−3
(9.5/25)
2.1 × 10
−5/4.3 × 10
−3
(2/46)
8.0 × 10
−4/3.0 × 10
−3
(8/29)
– 0.78/0.685
VEGFA 3.3 × 10
−3/1.4 × 10
−3
(16/19)
3.6 × 10
−3/2.2 × 10
−3
(22/25)
3.0 × 10
−3/2.0 × 10
−3
(22/20)
– 0.06/0.06
PIK3C2B 7.1 × 10
−3/6.1 × 10
−3
(33/45.5)
7.0 × 10
−3/9.3 × 10
−3
(39/75)
1.0 × 10
−2/7.0 × 10
−3
(43/40)
– 0.64/0.71
Q1 FLT1 <1.0 × 10
−4/<1.0 × 10
−4
(1.5/1.5)
4.2 × 10
−11/1.3 × 10
−5
(1/3)
<1.0 × 10
−4/<1.0 × 10
−4
(1.5/1.5)
<1.0 × 10
−7/<1.0 × 10
−7
(1/1)
1/1
KDR 5.0 × 10
−4/3.0 × 10
−4
(6/10)
5.3 × 10
−4/3.0 × 10
−4
(8/9)
7.0 × 10
−4/4.0 × 10
−4
(7/7)
1.2 × 10
−6/1.8 × 10
−7
(2/2)
0.995/0.99
HIF1A 9.8 × 10
−3/9.8 × 10
−3
(41/89.5)
1.0 × 10
−2/1.0 × 10
−2
(40.5/96)
2.4 × 10
−2/2.1 × 10
−2
(45/104)
1.1 × 10
−2/2.1 × 10
−2
(96/256)
0.655/0.61
VEGFA 1.4 × 10
−2/1.9 × 10
−3
(51/28)
1.5 × 10
−2/5.0 × 10
−4
(49.5/13)
3.0 × 10
−2/3.4 × 10
−3
(59/27)
2.2 × 10
−3/5.6 × 10
−4
(22/33)
0.015/0.485
ARNT 1.6 × 10
−2/9.0 × 10
−4
(56/19)
1.7 × 10
−2/1.5 × 10
−3
(63/24)
2.2 × 10
−2/1.9 × 10
−3
(44/18.5)
2.0 × 10
−2/5.9 × 10
−3
(156/128)
0.845/0.88
VEGFC 0.5/0.5
(956/1521)
0.502/0.502
(913/1313)
1/1
(1460/2083)
1.4 × 10
−3/1.4 × 10
−3
(19/63)
0.355/0.345
Q2 VNN3 8×1 0
−4/0.003
(2/7)
1.2 × 10
−2/2.2 × 10
−2
(9/40)
2.4 × 10
−3/7.0 × 10
−3
(5/12)
1.4 × 10
−3/2.4 × 10
−3
(6/19.5)
0.545/0.485
PDGFD 1.8 × 10
−2/3.6 × 10
−2
(30/113)
4.1 × 10
−2/6.5 × 10
−2
(46.5/118)
2.6 × 10
−2/4.5 × 10
−2
(27/79)
4.4 × 10
−2/5.2 × 10
−2
(238/420)
0.545/0.485
PLAT 1.6 × 10
−2/3.2 × 10
−1
(24/975)
6.3 × 10
−2/4.2 × 10
−1
(66/1030)
3.9 × 10
−2/9.2 × 10
−1
(46/1952)
1.2 × 10
−1/4.9 × 10
−1
(452/1960)
0.255/0.075
LPL 2.3 × 10
−2/4.1 × 10
−2
(42/124)
6.5 × 10
−2/8.1 × 10
−2
(70/172.5)
3.4 × 10
−2/9.8 × 10
−2
(40/186)
8.2 × 10
−2/2.2 × 10
−1
(1999/1166)
0.47/0.28
VNN1 1.2 × 10
−1/2.2 × 10
−1
(176/629)
1.6 × 10
−1/3.8 × 10
−1
(142/957)
2.2 × 10
−1/3.3 × 10
−1
(242/624)
1.9 × 10
−3/3.2 × 10
−1
(11/1468)
0.38/0.04
In each cell the top line lists the p-values and the values in parentheses give the corresponding ranks. Results are computed using nonsynonymous rare variants
(before slash) or all rare variants (after slash). Power is the replicability across 200 simulations using the WS method. Genes are sorted by their p-values in the WS
method using nonsynonymous rare variants.
Fan et al. BMC Proceedings 2011, 5(Suppl 9):S17
http://www.biomedcentral.com/1753-6561/5/S9/S17
Page 3 of 5rare variants with strong effect that show up in extreme
phenotypes. Genes identified by dichotomization tend to
have high power because the statistical signal can be
consistently detected after removing unidentifiable
noise. Therefore selecting extreme phenotypes can
sometimes be an alternative strategy in dealing with
quantitative traits. On the other hand, these two strate-
gies both detect the same disease genes: FLT1 and KDR
for Q1 and VNN3 f o rQ 2 ,w h i c hm a ys u g g e s tt h a tt h e y
are true positives.
Overall, our results are encouraging on these simu-
lated data. In particular, we successfully detected six
true disease genes for Q1, five for Q2, and three for
Affected Status in the top 50 most significant genes
using only the first simulated data set.
Replicability across 200 simulations
Many of the disease genes are highly replicable in 200
simulations with power greater than 50% (Table 1), indi-
cating a potentially true signal. However, there are
numerous consistent false-positive genes showing high
replicability. Some top genes identified in the first
simulation, such as GOLGA1 for Affected Status,
PPP1R14BP1 for Q1, and MAP3K8 for Q2, all have
power greater than 50% (data not shown). This can hap-
pen for various reasons. Both sequencing errors and
population stratification can create these replicable false
signals, especially in these data sets, where the genotype
data are fixed across simulations. Another reason might
be long-range correlation between markers. Our investi-
gation showed that certain consistent false positives are
highly correlated with true causal SNPs and that it is
difficult to eliminate this artificial linkage effect because
of the fixed-genotype design across all simulations.
Filtering variants based on known functional predictions
We compared the results using only nonsynonymous rare
variants with those using all rare variants and observed
that nonsynonymous rare variants improve the rank of
true disease genes and the power for most disease genes,
especially for trait Q2 (Table 1). This is because the true
disease model includes only nonsynonymous mutations.
This may hold true for real data as well because most
rare variants are missense mutations and can change
gene expression level or protein function directly. Hence
focusing on nonsynonymous mutations helps to increase
signal-to-noise ratio for real risk factors.
Pathway analysis
We collapsed the rare SNPs (MAF < 0.05) in the VEGF
pathway and evaluated their effects on traits Affected
Status and Q1 using different statistical strategies (Table
2). The WS and RB methods performed substantially
better than the CMC method, probably because of the
increased power of weighted-sum approaches for large
genomic regions. The CMC approach has decreased
power as the region size increases because more indivi-
duals will be carriers of rare mutations by chance. Also,
using nonsynonymous variants results in a lower p-value
than using all variants does; this is consistent with pre-
vious gene-based analyses and emphasizes again that fil-
tering nonsynonymous mutations is important for
identifying influential rare SNPs.
Conclusions
In this study, we applied three statistical methods to
detect rare variants and successfully pinpointed several
true disease genes containing rare SNPs in the GAW17
data sets. We started with the first data set and then
made use of the remaining 199 replicates to evaluate the
replicability of the discoveries in the first data set. This
strategy agrees with the natural procedure when dealing
with real data; namely, a first data set is used for discov-
ery purposes, and additional independent data sets are
used for replication purposes. We showed that using 5%
as the MAF cutoff is better than using 1% in the
GAW17 data set because the current sample size is
small and disease variants occur at higher frequencies as
well. Also, including only nonsynonymous mutations
can substantially increase the signal. We also showed
that selection of extreme phenotypic individuals can be
a useful strategy for rare variant analysis with quantita-
tive traits. Our analyses encountered the difficulty of
numerous false positives, some probably resulting from
sequencing errors or population stratification. Neverthe-
less, in real life without knowledge of the true model,
the methods we investigated here can help us to detect
rare disease SNPs. The consistency of results from dif-
ferent methods can be an indicator of true signal. The
three methods performed similarly for the disease genes
Table 2 p-value of the VEGF pathway for Affected Status and Q1 in the first simulation using different methods
Affected Status Q1, dichotomized Q1 (Price et al. [9])
CMC WS RB CMC WS RB
Rare NS 0.00287 <0.0001 <0.0001 2.938 × 10
−6 <0.0001 <0.0001 <0.0001
Rare 0.06721 0.02 0.0003 0.02687 <0.0001 <0.0001 <0.0001
Results from using only nonsynonymous rare variants (Rare NS) and all rare variants (Rare) are shown here. p-values for the WS and RB methods are computed
based on 10,000 permutations.
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replication-based approach was the most powerful
approach for large genetic regions such as pathways, fol-
lowed by the weighted-sum and collapsing approaches.
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